AlloVir, Inc. Stock News

Gilead has purchased $10.9 million in shares of Allovir, a biotech company specializing in cell therapy and organ transplant, giving it a 15% ownership of the company. Allovir's lead product, posoleuc

Positive final results from the phase 2 study, using posoleucel for BK Virus, were presented at the American Transplant Congress 2023. Discussions with FDA and key opinion leaders to align on phase 3

AlloVir, Inc. (ALVR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AlloVir stock fell to a 52-week low on Thursday. The company's lead therapy has begun phase 3 trials to treat kidney transplant patients who had virus infections.

AlloVir (NASDAQ: ALVR ) stock is falling hard on Thursday after the company announced the pricing of a public share offering. That offering has AlloVir selling 20 million shares of ALVR stock for $3.7

AlloVir is a clinical-stage biotech that focuses on viral therapies. The company has only enough cash to fund operations into early 2024.

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will p

The consensus price target hints at a 281.4% upside potential for AlloVir, Inc. (ALVR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es

AlloVir, Inc. (ALVR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 355.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a

WALTHAM, Mass.--( BUSINESS WIRE )--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will

AlloVir, Inc. has some solid data in an area of unmet need. AlloVir is well-capitalized to complete its trials.

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will p

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.